Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01266135 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: QAX576
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals